Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: A critical assessment

被引:32
作者
Raddatz, Rita
Schaffhauser, Herve
Marino, Michael J.
机构
关键词
drug discovery; G-protein-coupled receptor; allosteric; orthosteric;
D O I
10.1016/j.bcp.2007.05.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In recent years, the concept of allosteric modulation of G-protein-coupled receptors (GPCRs) has matured and now represents an increasingly viable approach to drug discovery. This is evident in the fact that allosteric modulators have been reported for every class of GPCR, and several are currently in clinical trials with one drug example approved and launched. The allosteric approach has been highlighted for the potential of identifying highly selective compounds with a minimal propensity to produce adverse effect. While much has been written regarding the promises of this approach, important challenges, caveats, and pitfalls exist that are often overlooked. Therefore, a balanced overview of the field that describes both the promises and the challenges of discovering allosteric modulators of GPCRs as novel drugs is presented. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:383 / 391
页数:9
相关论文
共 60 条
[1]  
Bartolomeo AC, 2000, J PHARMACOL EXP THER, V292, P584
[2]   Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury [J].
Bertini, R ;
Allegretti, M ;
Bizzarri, C ;
Moriconi, A ;
Locati, M ;
Zampella, G ;
Cervellera, MN ;
Di Cioccio, V ;
Cesta, MC ;
Galliera, E ;
Martinez, FO ;
Di Bitondo, R ;
Troiani, G ;
Sabbatini, V ;
D'Anniballe, G ;
Anacardio, R ;
Cutrin, JC ;
Cavalieri, B ;
Mainiero, F ;
Strippoli, R ;
Villa, P ;
Di Girolamo, M ;
Martin, F ;
Gentile, M ;
Santoni, A ;
Corda, D ;
Poli, G ;
Mantovani, A ;
Ghezzi, P ;
Colotta, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (32) :11791-11796
[3]   Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes [J].
Birdsall, NJM ;
Farries, T ;
Gharagozloo, P ;
Kobayashi, S ;
Kuonen, D ;
Lazareno, S ;
Popham, A ;
Sugimoto, M .
LIFE SCIENCES, 1997, 60 (13-14) :1047-1052
[4]   Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease [J].
Bodick, NC ;
Offen, WW ;
Levey, AI ;
Cutler, NR ;
Gauthier, SG ;
Satlin, A ;
Shannon, HE ;
Tollefson, GD ;
Rasmussen, K ;
Bymaster, FP ;
Hurley, DJ ;
Potter, WZ ;
Paul, SM .
ARCHIVES OF NEUROLOGY, 1997, 54 (04) :465-473
[5]   About a new biological relation of high importance that the blood carbonic acid tension exercises on its oxygen binding. [J].
Bohr, C ;
Hasselbalch, K ;
Krogh, A .
SKANDINAVISCHES ARCHIV FUR PHYSIOLOGIE, 1904, 16 :402-412
[6]   G protein-coupled receptor allosterism and complexing [J].
Christopoulos, A ;
Kenakin, T .
PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :323-374
[7]   Pharmacology and functions of metabotropic glutamate receptors [J].
Conn, PJ ;
Pin, JP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :205-237
[8]   3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity [J].
Cosford, NDP ;
Tehrani, L ;
Roppe, J ;
Schweiger, E ;
Smith, ND ;
Anderson, J ;
Bristow, L ;
Brodkin, J ;
Jiang, XH ;
McDonald, I ;
Rao, S ;
Washburn, M ;
Varney, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (02) :204-206
[9]  
DENIS Y, 2005, BIOORG MED CHEM LETT, V15, P3713
[10]  
EHLERT FJ, 1988, MOL PHARMACOL, V33, P187